American Journal of Ophthalmology
Volume 145, Issue 5 , Pages 862-874.e3 , May 2008

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results

  • Andrew N. Antoszyk

      Affiliations

    • Charlotte Eye, Ear, Nose and Throat Associates, Charlotte, North Carolina
    • Corresponding Author InformationInquiries to Andrew N. Antoszyk, Charlotte Eye, Ear, Nose and Throat Associates, 6035 Fairview Road, Charlotte, NC 28210
    • ,
  • Lisa Tuomi

      Affiliations

    • Genentech, Inc, South San Francisco, California.
    • ,
  • Carol Y. Chung

      Affiliations

    • Genentech, Inc, South San Francisco, California.
    • ,
  • Angele Singh

      Affiliations

    • Genentech, Inc, South San Francisco, California.
    • ,
  • FOCUS Study Group

,Accepted 22 December 2007.

References 

  1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  3. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of two randomized clinical trials—TAP Report No. 1. Arch Ophthalmol. 1999;117:1329–1345
  4. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials—TAP Report No. 2. Arch Ophthalmol. 2001;119:198–207
  5. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (Year 1 results of the FOCUS Study). Arch Ophthalmol. 2006;124:1532–1542
  6. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048–1053
  7. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:623–632
  8. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multi-dose study. Ophthalmology. 2006;113:633–642
  9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  10. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report No. 4. Retina. 2004;24:1–12
  11. Schlötzer-Schrehardt U, Viestenz A, Naumann GOH, Laqua H, Michels S, Schmidt-Erfurth U. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002;240:748–757
  12. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–560
  13. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Ophthalmology. 2008;145:239–248

 Supplemental Material available at AJO.com.

PII: S0002-9394(08)00008-1

doi: 10.1016/j.ajo.2007.12.029

American Journal of Ophthalmology
Volume 145, Issue 5 , Pages 862-874.e3 , May 2008

Article Tools

* Image Usage & Resolution